摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(4-chloro-2-fluorophenyl)piperazine-1-carboxylate | 945422-81-1

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(4-chloro-2-fluorophenyl)piperazine-1-carboxylate
英文别名
1-Boc-4-(4-chloro-2-fluorophenyl)piperazine
tert-butyl 4-(4-chloro-2-fluorophenyl)piperazine-1-carboxylate化学式
CAS
945422-81-1
化学式
C15H20ClFN2O2
mdl
——
分子量
314.787
InChiKey
GNUHDAKKEDREMW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    404.0±45.0 °C(Predicted)
  • 密度:
    1.229±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    32.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 储存条件:
    存储条件:2-8°C,避光,惰性气体环境中保存。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Piperazines and Piperidines as Mglur5 Potentiators
    申请人:Slassi Abdelmalik
    公开号:US20090023711A1
    公开(公告)日:2009-01-22
    Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: wherein Ar 1 , Ar 2 , A, X, Y, m, n and R 1 , R 2 , R 3 , R 4 and R 5 are as described in the specification, processes for their preparation, pharmaceutical formulations comprising them and their use in therapy, particularly in the therapy of neurological and psychiatric disorders associated with glutamate dysfunction.
    公式I的化合物或其药学上可接受的盐或溶剂化物:其中Ar1,Ar2,A,X,Y,m,n和R1,R2,R3,R4和R5如说明书所述,其制备方法,包括它们的药物制剂以及它们在治疗中的应用,特别是在与谷氨酸功能障碍相关的神经系统和精神障碍的治疗中。
  • [EN] SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS<br/>[FR] ACIDES PYRAZOLYLPIPÉRIDINE CARBOXYLIQUES SUBSTITUÉS
    申请人:BAYER AG
    公开号:WO2022122916A1
    公开(公告)日:2022-06-16
    The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    本发明涉及取代的吡唑啉哌啶羧酸、其盐以及其制备方法,以及它们用于制备治疗和/或预防疾病的药物,特别是心血管和心脏疾病,优选为降低和保留射血分数的心力衰竭(HFrEF,HFmrEF和HFpEF)、高血压(HTN)、周围动脉疾病(PAD,PAOD)、心肾和肾脏疾病,优选为慢性和糖尿病性肾脏疾病(CKD和DKD)、心肺和肺部疾病,优选为肺动脉高压(PH),以及其他疾病,优选为神经退行性疾病和不同形式的痴呆症、纤维性疾病、系统性硬化(SSc)、镰状细胞病(SCD)、创伤愈合障碍,如糖尿病足溃疡(DFU)。
  • [EN] MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE<br/>[FR] MODULATEURS DE CANAUX TRPML, LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION
    申请人:CARAWAY THERAPEUTICS INC
    公开号:WO2022150461A1
    公开(公告)日:2022-07-14
    The present disclosure relates to methods of treating a ciliopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition thereof, wherein the compound modulates a TRPML ion channel. The disclosure also relates to pharmaceutical compounds of Formula (III) and subformulas thereof, or a pharmaceutically acceptable salt or composition thereof, and methods of their use for modulating TRPML ion channels, and for treating disorders.
    本公开涉及治疗纤毛病的方法,该方法包括向需要治疗的患者施用化合物或其制剂的治疗有效量,其中该化合物调节TRPML离子通道。本公开还涉及公式(III)及其亚式化合物的药物化合物,或其药学上可接受的盐或制剂,以及用于调节TRPML离子通道和治疗疾病的方法。
  • Piperazine derivatives as TRPML modulators
    申请人:CalyGene Biotechnology, Inc.
    公开号:US10851084B2
    公开(公告)日:2020-12-01
    The new piperazine derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, and ageing.
    新的哌嗪衍生物是 TRPML 的调节剂,可用于治疗与 TRPML 活性有关的疾病,如溶酶体贮积症、肌肉萎缩症、与年龄有关的常见神经退行性疾病、与氧化应激或活性氧(ROS)有关的疾病以及老化。
  • Tricyclic degraders of Ikaros and Aiolos
    申请人:C4 Therapeutics, Inc.
    公开号:US11407732B1
    公开(公告)日:2022-08-09
    Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
    介绍了用于治疗的三环脑龙结合剂,可通过泛素蛋白酶体途径降解 Ikaros 或 Aiolos。
查看更多